Please enter exact key words
A Novel Monoclonal Antibody Against GIPR and GLP-1R

for the Treatment of Diabetes and Obesity

Home / Available Projects / A Novel Monoclonal Antibody Against GIPR and GLP-1R
Drug Name GPCR-targeted Project 013

A monoclonal antibody against glucose-dependent insulinotropic peptide receptor (GIPR) that fused glucagon-like peptide-1 (GLP-1) fragment is being developed for the treatment of type II diabetes mellitus and obesity. The engineered antibody was shown to target both GIPR and GLP-1R to decrease appetite and accumulation of body fat in preclinical studies.

Target Glucose-dependent insulinotropic peptide receptor (GIPR); Glucagon-like peptide-1 receptor (GLP-1R)
Drug Modality Monoclonal antibody
Indication Type 2 diabetes mellitus; Obesity
Product Category Biologic
Mechanism of Action GIPR antagonists; GLP-1R modulators
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. More offices have been established at different locations across China and the US ever since.

Protheragen Inc.